Advocacy intelligence hub — real-time data for patient organizations
COAGADEX: FDA approved
in adults and children with hereditary Factor X deficiency for routine prophylaxis to reduce the frequency of bleeding episodes; on-demand treatment and control of bleeding episodes; and perioperative management of bleeding in patients with mild, moderate, and severe hereditary Factor X deficiency
ALTUVIIIO: FDA approved
in adults and children with hemophilia A (congenital factor VIII deficiency) for routine prophylaxis to reduce the frequency of bleeding episodes; on-demand treatment and control of bleeding episodes; and perioperative management of bleeding
Pfizer — PHASE4
ALPROLIX: FDA approved
Adults and children with Hemophilia B for control and prevention of bleeding episodes, perioperative management, and routine prophylaxis to prevent or reduce the frequency of bleeding episodes.
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Open now
Copay cards
Copay Assistance1
ALPROLIX
Bioverativ Therapeutics, Inc.
COAGADEX
(Coagulation factor X (human))Orphan drugBio Products Laboratory Limited
12.1 Mechanism of Action COAGADEX temporarily replaces the missing Factor X needed for effective hemostasis. Factor X is an inactive zymogen, which ca...
ALTUVIIIO
(ANTIHEMOPHILIC FACTOR (RECOMBINANT), FC-VWF-XTEN FUSION PROTEIN-EHTL)Orphan drugBioverativ Therapeutics Inc.
ALPROLIX
(Coagulation factor IX (recombinant), Fc fusion protein)Orphan drugBioverativ Therapeutics, Inc.
Browse all Multisystem inflammatory syndrome in children and adults news →
View all Multisystem inflammatory syndrome in children and adults specialists →